Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor MUD versus HLA-Haploidentical Related Haplo Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults AYA with Acute Leukemia or Myelodysplastic Syndrome MDS
Study Type: Treatment
Phase: III
NCTID: NCT05457556
Principal Investigator:
Ibrahim Ahmed
A Phase II trial of Pevonedistat and Azacitidine in MDS or MDS/MPN patients who fail primary therapy with DNA methyl transferase inhibitors
A First-in-Human FIH, Phase 1, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Orally Administered GLB-001 in Patients with Refractory or Relapsed Acute Myeloid Leukemia R/R AML or Refractory or Relapsed Higher-risk Myelodysplastic Syndromes R/R HR-MDS
Study Type: Treatment
Phase: I
NCTID: NCT06146257
Principal Investigator:
Jesus Gonzalez Lugo
Phase I/IB Open-Label, Dose-Escalation Study of APVO436 in Patients With Relapsed or Refractory AML or High-Grade MDS
A Phase IIA, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 a Liposomal Grb2 Antisense Oligonucleotide in Combination with Venetoclax plus Decitabine in Patients with Acute Myeloid Leukemia AML Who Are Ineligible for Intensive Induction Therapy
Phase IIIb, Open-label study evaluating the efficacy and safety of luspatercept BMS-986346/ACE-536 initiated at maximum approved dose in LR-MDS with IPSS-R very low, low or intermediate risk who require RBC transfusions MAXILUS
Study Type: Treatment
Phase: III
NCTID: NCT06045689
Principal Investigator:
Jesus Gonzalez Lugo
A Randomized, Open-Label, Phase I/II Study of ASTX727 Low Dose ASTX727 LD Extended Schedule in Subjects with Lower Risk IPSS Low or Intermediate-1 Myelodysplastic Syndromes MDS
Venetoclax In Combination with ASTX727, an All-ORal TherapY for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts VICTORY-MDS/MPN: a Randomized, Phase II trial
Randomized Phase II Study of daunorubicin and cytarabine liposome + Pomalidomide versus daunorubicin and cytarabine liposome in Newly Diagnosed AML with MDS-Related Changes.
Study Type: Treatment
Phase: II
NCTID: NCT04802161
Principal Investigator:
Jesus Gonzalez Lugo